Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2022 Feb 12;113(2):335–344. doi: 10.1016/j.ijrobp.2022.02.014

Table 2B.

Patient and Treatment Characteristics

No. of Patients (%)

Characteristic DDR WT or VUS (n = 74) DDR mt (n = 15) p – value

Age 0.951
 Median, Range (years) 68 (46 – 83) 69 (52 – 80)

Ever Smoker 0.406
 Yes 57 (77) 13 (87)

Sex 0.720
 Female 48 (65) 9 (60)
 Male 26 (35) 6 (40)

Performance Status 0.523
 ECOG 0 46 (62) 8 (53)
 ECOG 1 28 (38) 7 (46)

Histology 0.9
 Adenocarcinoma 65 (88) 13 (87)
 Other 9 (12) 2 (13)

Tumor Mutational Burden 0.003
 Median, IQR (mt/Mb) 6.1 (3–10.5) 14 (7.9–19.4)

AJCC 8th Overall Stage 0.182
 < III 8 (11) 0
 IIIA or IIIB 66 (89) 15 (100)

Margin Status 0.9
 Negative 65 (88) 13 (87)
 Positive 9 (12) 2 (13)

Involved Mediastinal Nodal Stations 0.314
 <2 54 (73) 9 (60)
 ≥2 20 (27) 6 (40)

Received Chemotherapy 0.778
 Yes 66 (89) 13 (87)

Received ICI 0.397
 Yes 11 (15) 1 (7)

Received TKI 0.587
 Yes 9 (12) 1 (7)

Radiation Dose 0.616
 Median, range (Gy) 54 (50 – 60) 54 (50 – 60)

Radiation Technique
 3D-CRT 16 (22) 2 (13) 0.862
 IMRT 58 (78) 13 (87)